|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 2 | LAMOST Experiment for Galactic Understanding and Exploration (LEGUE)——The survey's science plan显示文摘We describe the current plans for a spectroscopic survey of millions of stars in the Milky Way galaxy using the Guo Shou Jing Telescope (GSJT, formerly called the Large sky Area Multi-Object fiber Spectroscopic Telescope - LAMOST). The survey will obtain spectra for 2.5 million stars brighter than r < 19 during dark/grey time, and 5 million stars brighter than r < 17 or J < 16 on nights that are moonlit or have low transparency. The survey will begin in the fall of 2012, and will run for at least four years. The telescope's design constrains the optimal declination range for observations to 10 < δ < 50 , and site conditions lead to an emphasis on stars in the direction of the Galactic anticenter. The survey is divided into three parts with different target selection strategies: disk, anticenter, and spheroid. The resulting dataset will be used to study the merger history of the Milky Way, the substructure and evolution of the disks, the nature of the first generation of stars through identification of the lowest metallicity stars, and star formation through study of open clusters and OB associations. Detailed design of the LAMOST Experiment for Galactic Understanding and Exploration (LEGUE) survey will be completed in summer 2012, after a review of the results of the pilot survey. | Li-Cai Deng Heidi Jo Newberg Chao Liu Jeffrey L. Carlin Timothy C. Beers Li Chen Hsu-Tai Lee Carl J. Grillmair Puragra Guhathakurta] Zhan-Wen Han Jin-Liang Hou Sebastien Lepine Jing Li Xiao-Wei Liu Kai-Ke Pan J. A. Sellwood Bo Wang Hong-Chi Wang Fan Yang Brian Yanny Hao-Tong Zhang Yue-Yang Zhang Zheng Zheng Zi Zhu | 2012 | Research in Astronomy and Astrophysics2012，12，7： | 10 |
| 3 | Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma显示文摘 | CHEN Bo-bin XU Xiao-ping SHEN Lin HAN Tian-jie LIN Zhi-guang CHEN Zi KANG Hui HUANG Bo LIN Guo-wei | 2013 | Chinese Medical Journal2013，，3： | 6 |
| 4 | Routing valley exciton emission of a WS_(2) monolayer via delocalized Bloch modes of in-plane inversion-symmetry-broken photonic crystal slabs显示文摘The valleys of two-dimensional transition metal dichalcogenides(TMDCs)offer a new degree of freedom for information processing.To take advantage of this valley degree of freedom,on the one hand,it is feasible to control valleys by utilizing different external stimuli,such as optical and electric fields.On the other hand,nanostructures are also used to separate the valleys by near-field coupling.However,for both of the above methods,either the required low-temperature environment or low degree of coherence properties limit their further applications.Here,we demonstrate that all-dielectric photonic crystal(PhC)slabs without in-plane inversion symmetry(C_(2) symmetry)can separate and route valley exciton emission of a WS2 monolayer at room temperature.Coupling with circularly polarized photonic Bloch modes of such PhC slabs,valley photons emitted by a WS_(2) monolayer are routed directionally and are efficiently separated in the far field.In addition,far-field emissions are directionally enhanced and have long-distance spatial coherence properties. | Jiajun Wang Han Li Yating Ma Maoxiong Zhao Wenzhe Liu Bo Wang Shiwei Wu Xiaohan Liu Lei Shi Tian Jiang Jian Zi | 2020 | Light(Science & Applications)2020，9，1： | 4 |
| 5 | Dual-modality magnetic resonance/optical imaging-guided sonodynamic therapy of pancreatic cancer with metal-organic nanosonosensitizer显示文摘Sonodynamic therapy(SDT)has been more attractive to carry out oncology treatments in recent years.However,imagingguided sonodynamic therapeutic nanomedicine is still a shortage in SDT development.In this work,we designed and fabricated an organic SDT system based on combination of 1,2,4,5-tetrakis(4-carboxyphenyl)-porphyrin(TCPP)and gadolinium(III)(Gd^(3+))creatively(Gd-PPNs).Gd^(3+)was traditionally used to be T_(1)-weighted magnetic resonance imaging(MRI)contrast agent and TCPP was initiatively a fluorescence imaging organic media.Therefore,these new designed nanoparticles have immense potential to integrate MRI and FLI to visualize the Gd-PPNs accumulating and keeping in tumor for a long time,which could be applied for guidance of SDT on tumors in clinical practice.Importantly,excellent SDT efficiency under imaging guidance was verified both in vitro and in vivo in this work.Our findings suggested that Gd-PPNs,as innovative imaging and therapy combinational nanomedicines,were successfully synthesized and were proved to possess excellent imaging-guided sonodynamic therapeutic efficacy.Moreover,this new designed sonosensitizer had great biocompatibility to avoid unnecessary biotoxicity.Overall,this strategy shed light on the MRI/FLI-guidance and successfully induced pancreatic tumor growth inhibition by sonodynamic therapy. | Yingli Chen Bo Yin Zhuang Liu Han Wang Zi Fu Xiuru Ji Wei Tang Dalong Ni Weijun Peng | 2022 | Nano Research2022，15，7： | 0 |
| 6 | Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants:a randomized phase 2 trial显示文摘An ongoing randomized,double-blind,controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate,named NVSI-06-09,as a booster dose in subjects aged 18 years and older from the United Arab Emirates(UAE),who had administered two or three doses of inactivated vaccine BBIBP-CorV at least 6 months prior to enrollment.The participants were randomly assigned with 1:1 to receive a booster dose of NVSI-06-09 or BBIBP-CorV.The primary outcomes were immunogenicity and safety against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)Omicron variant,and the exploratory outcome was cross-immunogenicity against other circulating strains.Between May 25 and 30,2022,516 adults received booster vaccination with 260 in NVSI-06-09 group and 256 in BBIBP-CorV group.Interim results showed a similar safety profile between two booster groups,with low incidence of adverse reactions of grade 1 or 2.For immunogenicity,by day 14 post-booster,the fold rises in neutralizing antibody geometric mean titers(GMTs)from baseline elicited by NVSI-06-09 were remarkably higher than those by BBIBP-CorV against the prototype strain(19.67 vs 4.47-fold),Omicron BA.1.1(42.35 vs 3.78-fold),BA.2(25.09 vs 2.91-fold),BA.4(22.42 vs 2.69-fold),and BA.5 variants(27.06 vs 4.73-fold).Similarly,the neutralizing GMTs boosted by NVSI-06-09 against Beta and Delta variants were also 6.60-fold and 7.17-fold higher than those by BBIBP-CorV.Our findings indicated that a booster dose of NVSI-06-09 was well-tolerated and elicited broad-spectrum neutralizing responses against divergent SARS-CoV-2 variants,including Omicron and its sub-lineages. | Nawal Al Kaabi Yun Kai Yang Yu Liang Ke Xu Xue Feng Zhang Yun Kang Yu Qin Jin Jun Wei Hou Jing Zhang Tian Yang Salah Hussein Mohamed Saif ElDein Ze Hua Lei Hao Zhang Shuai Shao Zhao Ming Liu Ning Liu Xiang Zheng Ji Guo Su Sen Sen Yang Xiangfeng Cong Yao Tan Wenwen Lei Xue Jun Gao Zhiwei Jiang Hui Wang Meng Li Hanadi Mekki Mekki Walid Zaher Sally Mahmoud Xue Zhang Chang Qu Dan Ying Liu Jing Zhang Mengjie Yang Islam Eltantawy Peng Xiao Fu Jie Shen Jin Juan Wu Zi Bo Han Li Fang Du Fang Tang Shi Chen Zhi Jing Ma Fan Zheng Ya Nan Hou Xin Yu Li Xin Li Zhao Nian Wang Jin Liang Yin Xiao Yan Mao Jin Zhang Liang Qu Yun Tao Zhang Xiao Ming Yang Guizhen Wu Qi Ming Li | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 0 |
| 7 | Establishment and Modification of Ninety-seven Pneumococcal Serotyping Assays Based on Quantitative Real-time Polymerase Chain Reaction显示文摘Objective To establish and modify quantitative real-time polymerase chain reaction(qPCR)-based serotyping assays to distinguish 97 pneumococcal serotypes.Methods A database of capsular polysaccharide(cps)loci sequences was generated,covering 97 pneumococcal serotypes.Bioinformatics analyses were performed to identify the cps loci structure and target genes related to different pneumococcal serotypes with specific SNPs.A total of 27 novel qPCR serotyping assay primers and probes were established based on qPCR,while 27 recombinant plasmids containing serotype-specific DNA sequence fragments were constructed as reference target sequences to examine the specificity and sensitivity of the qPCR assay.A panel of pneumococcal reference strains was employed to evaluate the capability of pneumococcal serotyping.Results A total of 97 pneumococcal serotyping assays based on qPCR were established and modified,which included 64 serotypes previously reported as well as an additional 33 serotypes.Twenty-seven novel qPCR serotyping target sequences were implemented in the pneumococcal qPCR serotyping system.A total of 97 pneumococcal serotypes,which included 52 individual serotypes and 45 serotypes belonging to 20 serogroups,could not be identified as individual serotypes.The sensitivity of qPCR assays based on 27 target sequences was 1–100 copies/μL.The specificity of the qPCR assays was 100%,which were tested by a panel of 90 serotypes of the pneumococcal reference strains.Conclusion A total of 27 novel qPCR assays were established and modified to analyze 97pneumococcal serotypes. | CHE Jie CHEN Bo Han XU Li GAO Yuan YUE Meng Meng CHEN Zi Man ZHANG Mao Jun SHAO Zhu Jun | 2023 | Biomedical and Environmental Sciences2023，36，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员